Renalytix (RENX,) has presented clinical data at the American Diabetes Association 83rd Scientific Sessions, showcasing the effectiveness of its in vitro prognostic tool, KidneyIntelX, in improving the health of patients with type 2 diabetes and chronic kidney disease.
The US currently has around 14 million adults affected by diabetic kidney disease, a number projected to more than double by 2060 due to increasing obesity and diabetes rates. KidneyIntelX is designed for use in patients with type 2 diabetes and stages 1-3 of kidney disease to assess which patients are at low, intermediate, or high risk for a rapid progressive decline in their kidney function.
The study, involving 2,317 real-world patients in New York City, revealed sustained improvements in diabetes and chronic kidney disease health over a year after using KidneyIntelX. High-risk patients experienced a significant decrease in hemoglobin levels, which indicates improved diabetes control. Moreover, the median estimated glomerular filtration rate slope, a measure of chronic kidney disease progression, showed a notable improvement in high-risk patients, suggesting a slowdown in disease advancement.
These findings highlight the importance of precision-based tools like KidneyIntelX in managing diabetic kidney disease and improving patient outcomes.
View from Vox
KidneyIntelX is a laboratory test that provides a clear risk score to predict the likelihood of fast kidney function decline in adult patients with type 2 diabetes and early-stage chronic kidney disease. This test helps doctors identify whether patients are at low, intermediate, or high risk for rapid progression of their kidney condition.
By combining the information from KidneyIntelX with newer treatments that protect the heart and kidneys, doctors can make more informed decisions about which patients are more likely to experience fast disease progression. This allows them to allocate resources and provide appropriate treatments according to guidelines, ultimately promoting better kidney health and arriving at improved patient outcomes.
Renalytix's development of KidneyIntelX is in response to significant medical demand. The majority of 37 million Americans with diabetes have type 2 diabetes, and, while type 2 diabetes is commonly seen in individuals over 45 years old, there is a concerning trend of younger individuals being diagnosed with the disease.
Demand for KidneyIntelX is augmented by the fact that many people remain undiagnosed, with approximately 23% of adults unaware they have type 2 diabetes. Furthermore, type 2 diabetes affects various vital organs such as the heart, blood vessels, nerves, eyes, and kidneys, with diabetic kidney disease developing in 30-50% of individuals with type 2 diabetes.
Renalytix's development of KidneyIntelX aims to address this pressing demand by providing a solution to assess the risk and progression of kidney disease in patients with type 2 diabetes.
Follow Renalytix for more News and Updates: